Description
Why It’s Done:
The test is ordered to:
• Diagnose CML or Ph+ ALL by detecting the BCR-ABL fusion gene
• Monitor minimal residual disease (MRD) and response to treatment in patients undergoing tyrosine kinase inhibitor therapy
• Detect relapse or disease progression
• Guide treatment decisions, including therapy adjustments
Preparation:
• No special preparation is needed.
• A blood sample or bone marrow aspirate is collected for analysis.
• Inform your healthcare provider about any recent treatments or medications.
• Results may take a few days depending on the lab.


